Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

J Clin Oncol · 2026 · PMC13340455 · PMID 42212672

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

In the kappa isotype population, there was also a favorable trend for anselamimab compared with placebo in 6MWT change at week 50 of 18.00 m (95% CI, –71.60 to 95.92 m).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.